Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC hydrogel technology, a cell-free, off-the-shelf implant designed to promote the regeneration of durable, natural-like cartilage in patients with painful knee cartilage injuries. The implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, and the company has reported greater pain improvement than traditional microfracture, according to Regentis Biomaterials (NYSE American: RGNT).
The company has treated 43 of 80 planned patients in its U.S. pivotal Phase III trial, with enrollment expected to conclude around the end of 2026. Regentis is also preparing for potential European commercialization under its existing CE Mark approval. The manufacturing scale-up follows European regulatory approval of a new solvent-free process that the company says increases production yield by 400%. This development matters because GelrinC aims to address a market of approximately 470,000 cartilage knee repair cases annually in the U.S. where no off-the-shelf treatment is available. A higher-yielding, solvent-free manufacturing process could help Regentis meet potential demand if the product gains broader approval and adoption.
For investors and industry observers, the combination of manufacturing scale-up, regulatory progress in Europe, and ongoing Phase III enrollment signals execution on multiple fronts. The full article can be viewed at https://nnw.fm/JiVLN, and the latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT. The content was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire, among other services. The dissemination was part of a paid investor awareness and marketing engagement on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT). Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
